Menu Search
Equities

Zoetis Inc

ZTS:NYQ

Zoetis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)197.20
  • Today's Change0.72 / 0.37%
  • Shares traded515.45k
  • 1 Year change+8.36%
  • Beta0.8752
Data delayed at least 15 minutes, as of Sep 19 2024 16:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform9
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Zoetis Inc have a median target of 225.00, with a high estimate of 248.00 and a low estimate of 172.12. The median estimate represents a 14.52% increase from the last price of 196.48.
High26.2%248.00
Med14.5%225.00
Low-12.4%172.12

Dividends in USD

In 2023, Zoetis Inc reported a dividend of 1.50 USD, which represents a 15.38% increase over last year. The 9 analysts covering the company expect dividends of 1.70 USD for the upcoming fiscal year, an increase of 13.53%.
Div growth (TTM)15.38%
More ▼

Earnings history & estimates in USD

On Aug 06, 2024, Zoetis Inc reported 2nd quarter 2024 earnings of 1.56 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 2nd quarter results by 10.64%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+2.99%
Zoetis Inc reported annual 2023 earnings of 5.32 per share on Feb 13, 2024.
Average growth rate+10.17%
More ▼

Revenue history & estimates in USD

Zoetis Inc. had 2nd quarter 2024 revenues of 2.36bn. This bettered the 2.31bn consensus of the 10 analysts covering the company. This was 18.05% above the prior year's 2nd quarter results.
Average growth rate+2.08%
Zoetis Inc. had revenues for the full year 2023 of 8.54bn. This was 5.74% above the prior year's results.
Average growth rate+8.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.